Bcma chimeric antigen receptors

a technology of chimeric antigen receptors and bcma, which is applied in the direction of viruses, vectors, fusion polypeptides, etc., can solve the problems of humanized anti-bcma cars unsuitable for t cell therapy, and achieve the effect of treating, preventing, or ameliorating b cell related conditions

Inactive Publication Date: 2017-08-10
2SEVENTY BIO INC
View PDF2 Cites 52 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008]The invention generally provides improved vectors for generating T cell therapies and methods of using the same. More particularly,

Problems solved by technology

Without wishing to be bound to any particular theory, the inventors have discovered that certain humanized anti-BCMA CARs elicit antigen

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bcma chimeric antigen receptors
  • Bcma chimeric antigen receptors
  • Bcma chimeric antigen receptors

Examples

Experimental program
Comparison scheme
Effect test

example 1

Construction of Anti-BCMA Cars

[0401]CARs containing humanized anti-BCMA scFv antibodies were designed to contain an MND promoter operably linked to anti-BCMA scFv, a hinge and transmembrane domain from CD8α and a CD137 co-stimulatory domains followed by the intracellular signaling domain of the CD3ζ chain. FIG. 1. The anti-BCMA CARs comprise a CD8α signal peptide (SP) sequence for the surface expression on immune effector cells. The polynucleotide sequences of the anti-BCMA CARs are set forth in SEQ ID NOs: 30 to 44, 70, and 72; polypeptide sequences of the anti-BCMA CARs are set forth in SEQ ID NOs: 15 to 29, 71, and 73; and the vector maps is shown in FIG. 1. Tables 3 to 5 show the Identity, Genbank Reference, Source Name and Citation for the various nucleotide segments of various exemplary anti-BCMA CAR lentiviral vectors.

TABLE 3NucleotidesIdentityGenBank ReferenceSource NameCitation  1-185pUC19 plasmidAccession #L09137.2pUC19New Englandbackbonent 1-185Biolabs 185-222LinkerNot ap...

example 2

High Throughput Screen of Humanized Anti-BCMA Car

[0402]A microculture assay was developed to rapidly screen anti-BCMA CARs. The microculture assay can compare 15-20 CAR modified T cells (CART cells). Peripheral blood mononuclear cells (PBMC) were cultured in 24-well plates in media containing IL-2 (CellGenix) and antibodies specific for CD3 and CD28 (Miltenyi Biotec) to initiate outgrowth of T cells. The expanded T cells were >99% CD3 positive T cells after 7 days of culture.

[0403]T cells expanded from PBMC were modified by lentiviruses to express the anti-BCMA CARs. Transient lentiviral supernatants were added to the PBMC culture at 1:1 ratio (volume:volume) one day after culture initiation. Cultures were split as needed with fresh media containing IL-2 after becoming optically confluent using an inverted light microscope. After twelve days of culture, CAR T cells were harvested and evaluated for CAR expression and function.

[0404]Expression of CARs on the T cell surface was assayed...

example 3

Antigen Specific Reactivity of Car T Cells

[0405]Antigen-specific reactivity was examined after co-culture with BCMA-positive cell lines. Anti-BCMA CAR T cells were co-cultured with BCMA-engineered K562 (K562-BCMA) cells for 24 hours. Reactivity of the anti-BCMA CAR T cells to K562-BCMA was assayed by IFN-gamma (IFNγ) release into the supernatant by ELISA. All humanized anti-BCMA CART cells tested released similar amounts of IFNγ and the amounts were comparable the parental mouse anti-BCMA CAR. FIG. 2. In contrast, IFNγ was not detected in cultures containing either untransduced or CD19-specific CAR T cells confirming that BCMA-specificity of the CAR T cells was required for reactivity to K562-BCMA cells.

[0406]In another set of experiments, tumor cytolytic activity of T cells expressing one of five humanized anti-BCMA CARs was examined. anti-BCMA CAR T cells were co-cultured with K562-BCMA cells for four hours. The five humanized anti-BCMA CAR T cells exhibited similar cytolytic acti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides improved compositions for adoptive T cell therapies for B cell related conditions.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 62 / 028,664, filed Jul. 24, 2014, U.S. Provisional Application No. 62 / 044,103, filed Aug. 29, 2014, and U.S. Provisional Application No. 62 / 152,575, filed Apr. 24, 2015, each of which is incorporated by reference herein in its entirety.STATEMENT REGARDING SEQUENCE LISTING[0002]The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is BLBD_037_03WO_ST25.txt. The text file is 124 KB, was created on Jul. 23, 2015, and is being submitted electronically via EFS-Web, concurrent with the filing of the specification.BACKGROUND[0003]Technical Field[0004]The present invention relates to improved compositions and methods for treating B cell related conditions. More particularly, the inv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/28C12N15/86A61K39/395C07K14/705A61K38/17
CPCC07K16/2878C12N2830/60C07K14/70503C07K14/70521C07K14/70578A61K38/1774A61K38/177A61K39/3955C12N15/86C07K2317/24C07K2319/10C07K2319/03C07K2319/02C07K2317/622C07K2317/565C07K2317/56C07K2317/53C07K2317/524C07K2317/526A61K2039/572C12N2740/15043C12N2830/48C12N2830/50C07K14/70517C07K14/7051A61K2039/5156C07K2319/33C07K2317/73A61P13/12A61P17/00A61P19/02A61P21/04A61P25/00A61P29/00A61P35/00A61P35/02A61P37/00A61P37/02A61P37/06A61P37/08A61P7/00A61P7/06A61P9/00C07K2319/00
Inventor MORGAN, RICHARDFRIEDMAN, KEVIN
Owner 2SEVENTY BIO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products